tion). The majority of studies show either a correlation of tyrosine kinase activity with learning, or show that blockade of tyrosine kinases can impair synaptic plasticity or memory. However, it has yet to be shown that direct activation of tyrosine kinases can actually facili- 
; 180.3% Ϯ 16.3%, t 7 ϭ 5.84, p Ͻ 0.01). There was also of tyrosine kinases alone is sufficient to induce LTF, but LTF normally requires additional signals derived from 5HT. a significant difference between the 5HT alone and the bpV ϩ 5HT groups (t 12 ϭ 2.77, p Ͻ 0.02). Thus, activation of endogenous tyrosine kinases is able to substitute for Alteration of Tyrosine Kinase Activity Does Not Affect Short-Term Synaptic Facilitation several 5HT pulses, thereby lowering the threshold for the induction of LTF.
To test whether activation of tyrosine kinases was specific to long-term processes, we examined the effects Preparations treated with bpV alone, as a group, did not show significant LTF compared to baseline of both tyrosine kinase and tyrosine phosphatase inhibitors during the induction of short-term facilitation (STF), (153.1% Ϯ 33.9%, t 7 ϭ 1.46, NS). However, three out of eight preparations treated with bpV alone showed which normally persists for up to 20 min following a exhibited by these two groups (t 16 ϭ 0.37, NS We next examined translation. The immunosuppresant rapamycin has been shown to block a specific subset of protein synthesis that is stimulated downstream of growth factor receptors (Brown and Schreiber, 1996) . Moreover, 5HT-induced increases in translation have been shown to be sensitive to rapamycin (Yanow et To further examine the hypothesis that BDNF was accessing the same tyrosine kinase signaling cascade as bpV, we asked whether the facilitated LTF induced by BDNF ϩ 5HT required MAPK activation. U0126 or its inactive analog, U0124, was applied before and during the induction of LTF by BDNF ϩ 5HT. Significant LTF was induced in preparations treated with the inactive isomer (Figures 7C and 7D ; 160.1% Ϯ 6.8%, t 3 ϭ 7.01, p Ͻ 0.01), but the induction of LTF was blocked in preparations treated with U0126 (79.7% Ϯ 12.8%, t 3 ϭ 1.14, NS). Furthermore, there was significantly greater facilitation in the control group compared to the group exposed to the inhibitor (t 6 ϭ 5.56, p Ͻ 0.01). Application of U0126 had no effect on the induction of STF measured immediately after the single pulse of 5HT (data not shown; U0124 ϩ BDNF ϩ 5HT, 220.5% Ϯ 22.3%; U0126 ϩ BDNF ϩ 5HT, 238.7% Ϯ 26.9%, t 13 ϭ 0.52, NS). Thus, MAPK activity is required for LTF induced by BDNF ϩ 5HT. term memory as well, thus strengthening the generally lated ganglia were incubated with 50 g/ml of the drug for an hour data while paired comparisons were performed on the raw EPSP amplitudes. To assess facilitation above baseline, paired t tests before the start of the experiment. The drug was removed and the preparation was perfused for at least 30 min before the first pretest.
Activation of Tyrosine Kinases Induces Downstream Activation of MAPK
were used. Unpaired t tests were used for comparisons between two groups, while a factorial ANOVA followed by Fisher's PLSD post For the rapamycin experiments, 20 ml of ASW containing 200 nM rapamycin/0.1% DMSO (Calbiochem, La Jolla, CA) was perfused hoc analyses were used for comparisons among three or more groups. Differences were considered significant if p Ͻ 0.05 (two-30 min prior to application of bpV. At the 30 min time point, another 20 ml of ASW containing 200 nM rapamycin and 100 M bpV was tailed). To assess the difference in probability of inducing LTF between the bpV alone group and the bpV ϩ 5HT group, a chi-square perfused. The remainder of the procedure was identical to that described for the initial bpV experiments. The protocol used for the analysis was performed. Preparations were considered to exhibit LTF if the normalized EPSP amplitude at the long-term test was BDNF experiments was identical to that used for the bpV experiments. Ten milliliters of ASW containing 30 ng/ml BDNF (Calbio-130% or greater. Based on this criterion, preparations were sorted into LTϩ and LTϪ groups within the bpV alone and the bpV ϩ 5HT chem, La Jolla, CA) was applied to the preparation by perfusion after the third pretest. When the MEK inhibitor was used, 20 ml of treatment.
Western Blot Analysis 20 M U0126 or U0124 was perfused 30 min before application of BDNF. Another 10 ml of ASW containing 20 M U0126/U0124 and Since each experimental ganglia had a corresponding control from the same animal, the amount of MAPK activation is presented as a 30 ng/ml BDNF was perfused at the 30 min time point. The remainder of the experiment continued as described above.
percentage of the control value (e.g., ASW versus 5 ϫ 5HT, genistein versus genistein ϩ 5 ϫ 5HT, bpV treated versus ASW control, and bpV ϩ 5HT versus 5HT). For statistical analysis, difference scores Western Blot Analysis were obtained from the raw phospho-MAPK/total MAPK ratios beIsolated pleural-pedal ganglia were desheathed to expose the sotween treatments and controls (e.g., bpV-ASW), and a single sample mata of the tail SNs and the tail MNs. From each animal, one pair t test of the difference score was performed to assess significant of pleural-pedal ganglia was assigned to the experimental group MAPK activation. When comparing across treatment groups as in and the other pair served as a control. Experimental treatments were the comparison of bpV ϩ 5HT and bpV alone, an unpaired t test of identical to those used for the physiology experiments. Immediately the difference scores was used. In the comparison between a single after treatment, the SN cell cluster was excised from the pleural pulse of 5HT and ASW, an unpaired t test of the raw P-MAPK/ ganglion and cells were lysed in lysis buffer. Samples were sepatotal MAPK ratios was used because the ganglia in each of these rated using SDS-PAGE and transferred to nitrocellulose using stantreatment groups were from different animals but run on the same dard procedures. Blots were probed initially with phospho-p44/p42 blots. 
MAPK antibodies (Cell

